The roles of histone deacetylases and their inhibitors in cancer therapy

G Li, Y Tian, WG Zhu - Frontiers in cell and developmental biology, 2020 - frontiersin.org
Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

HDACs and HDAC inhibitors in cancer development and therapy

Y Li, E Seto - Cold Spring Harbor perspectives in …, 2016 - perspectivesinmedicine.cshlp.org
Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …

HMGA2 as a critical regulator in cancer development

B Mansoori, A Mohammadi, HJ Ditzel, PHG Duijf… - Genes, 2021 - mdpi.com
The high mobility group protein 2 (HMGA2) regulates gene expression by binding to AT-rich
regions of DNA. Akin to other DNA architectural proteins, HMGA2 is highly expressed in …

Inside HDACs with more selective HDAC inhibitors

J Roche, P Bertrand - European journal of medicinal chemistry, 2016 - Elsevier
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal
mainly against cancers, with four compounds approved by the Food and Drug …

The emerging roles of HDACs and their therapeutic implications in cancer

R Hai, D Yang, F Zheng, W Wang, X Han… - European Journal of …, 2022 - Elsevier
Deregulation of protein post-translational modifications is intensively involved in the etiology
of diseases, including degenerative diseases, inflammatory injuries, and cancers …

[HTML][HTML] Oncological role of HMGA2

S Zhang, Q Mo, X Wang - International journal of …, 2019 - spandidos-publications.com
The high mobility group A2 (HMGA2) protein is a non‑histone architectural transcription
factor that modulates the transcription of several genes by binding to AT‑rich sequences in …

Targeting histone deacetylases for cancer therapy: Trends and challenges

T Liang, F Wang, RM Elhassan, Y Cheng… - … Pharmaceutica Sinica B, 2023 - Elsevier
Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …

Characterization of histone deacetylase mechanisms in cancer development

R Hai, L He, G Shu, G Yin - Frontiers in Oncology, 2021 - frontiersin.org
Over decades of studies, accumulating evidence has suggested that epigenetic
dysregulation is a hallmark of tumours. Post-translational modifications of histones are …

Role of histone deacetylases in carcinogenesis: potential role in cholangiocarcinoma

K Pant, E Peixoto, S Richard, SA Gradilone - Cells, 2020 - mdpi.com
Cholangiocarcinoma (CCA) is a highly invasive and metastatic form of carcinoma with bleak
prognosis due to limited therapies, frequent relapse, and chemotherapy resistance. There is …

CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells

X Liu, F Tian, J Cui, L Gong, L Xiang, B Fan, S Liu… - Oncogene, 2023 - nature.com
Lung cancer is the leading cause of cancer-related death worldwide. KRAS mutations are
the most common oncogenic alterations found in lung cancer. Unfortunately, treating KRAS …